Lexeo Raises $100m To Advance CNS Candidates, Validate Cardiac Gene Therapies
Start-Up Has Brought In $185m In Less Than A Year
Executive Summary
The company, which has treatments in the clinic for CLN2 Batten disease and APOE4-associated Alzheimer’s disease, is developing AAV-mediated gene therapies designed for safer outcomes.
You may also be interested in...
Lexeo’s Approach To Gene Therapy For Common Conditions
Since becoming CEO of Lexeo a year before its launch, R. Nolan Townsend has steered the company from strength to strength, expanding its pipeline from three to eight novel therapeutics and ultimately developing therapeutics for a future where gene therapy can cut healthcare costs.
Gene Therapies: US Panel To Weigh Strategies For Preventing, Mitigating AAV Vector Toxicities
FDA seeks advice on screening patients potentially at higher risk for liver and other injuries, strategies to implement before or after gene therapy administration to head off or mitigate potential adverse events, and whether upper limits should be set for the total vector genome dose and total capsid dose.
Deal Watch: Seagen Ups Presence In HER2-Positive Cancer Field With RemeGen Deal
Lilly partners with Kumquat to discover small molecule IO drug. Kite, Appia Bio collaborate on allogeneic cell therapies. AstraZeneca and Regeneron pursue novel metabolic therapies targeting GPR75. Lexeo and Stelios merge to focus on gene therapies for rare cardiovascular indications.